Natus Medical Incorporated (NASDAQ:BABY) has been given an average rating of “Hold” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $46.50.

BABY has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Tuesday, October 24th. BidaskClub cut shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st.

TRADEMARK VIOLATION WARNING: “Natus Medical Incorporated (BABY) Given Average Rating of “Hold” by Analysts” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/11/05/natus-medical-incorporated-baby-given-average-rating-of-hold-by-analysts-2.html.

In other Natus Medical news, Director Robert A. Gunst sold 4,400 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $35.17, for a total value of $154,748.00. Following the transaction, the director now owns 50,850 shares in the company, valued at $1,788,394.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William M. Moore sold 3,000 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $34.10, for a total transaction of $102,300.00. Following the completion of the transaction, the director now owns 30,410 shares in the company, valued at approximately $1,036,981. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in BABY. Karp Capital Management Corp purchased a new position in shares of Natus Medical in the first quarter valued at about $242,000. Parametric Portfolio Associates LLC increased its position in shares of Natus Medical by 11.3% in the first quarter. Parametric Portfolio Associates LLC now owns 61,434 shares of the medical equipment provider’s stock valued at $2,411,000 after acquiring an additional 6,214 shares during the period. OppenheimerFunds Inc. boosted its stake in shares of Natus Medical by 26.7% during the 1st quarter. OppenheimerFunds Inc. now owns 8,026 shares of the medical equipment provider’s stock valued at $315,000 after purchasing an additional 1,689 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Natus Medical by 0.4% during the 1st quarter. Teachers Advisors LLC now owns 308,393 shares of the medical equipment provider’s stock valued at $12,104,000 after purchasing an additional 1,364 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Natus Medical by 17.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 217,848 shares of the medical equipment provider’s stock valued at $8,551,000 after purchasing an additional 32,800 shares in the last quarter. Hedge funds and other institutional investors own 94.44% of the company’s stock.

Shares of Natus Medical (NASDAQ BABY) traded up $0.55 during trading hours on Friday, reaching $42.65. 266,889 shares of the company were exchanged, compared to its average volume of 393,191. The stock has a market cap of $1,410.00, a PE ratio of 27.52 and a beta of 0.89. Natus Medical has a one year low of $31.65 and a one year high of $43.85. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. The company had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm’s revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.39 EPS. equities research analysts predict that Natus Medical will post 1.74 EPS for the current fiscal year.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.